Cargando…

Clinical outcomes in transient epileptic amnesia: A 10‐year follow‐up cohort study of 47 cases

OBJECTIVE: Transient epileptic amnesia (TEA) is a form of adult‐onset epilepsy where presenting features are well described, but little is known regarding prognosis. This study aimed to elucidate the long‐term prognosis of TEA regarding seizure control, memory, medical comorbidities, and life expect...

Descripción completa

Detalles Bibliográficos
Autores principales: Savage, Sharon A., Baker, John, Milton, Fraser, Butler, Christopher, Zeman, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310913/
https://www.ncbi.nlm.nih.gov/pubmed/35253220
http://dx.doi.org/10.1111/epi.17214
_version_ 1784753493582544896
author Savage, Sharon A.
Baker, John
Milton, Fraser
Butler, Christopher
Zeman, Adam
author_facet Savage, Sharon A.
Baker, John
Milton, Fraser
Butler, Christopher
Zeman, Adam
author_sort Savage, Sharon A.
collection PubMed
description OBJECTIVE: Transient epileptic amnesia (TEA) is a form of adult‐onset epilepsy where presenting features are well described, but little is known regarding prognosis. This study aimed to elucidate the long‐term prognosis of TEA regarding seizure control, memory, medical comorbidities, and life expectancy. METHODS: Up‐to‐date clinical information was collected for 47 people diagnosed with TEA who had joined the The Impairment of Memory in Epilepsy (TIME) study 10 years earlier. At entry to the study, information about comorbid conditions was systematically collected. Details regarding subsequent diagnoses, seizure activity, changes to treatment, or reports of cognitive impairment were obtained through the family doctor. The variables of interest were compared with UK population data. RESULTS: Mortality in the cohort was 21 of 47 (45%), with an average age at death of 82.5 years. Seizures remained well controlled for the majority but medications required adjustments in dose and type for some (28%). A small number (three cases) remained seizure‐free without medication. History of cardiovascular disorders was frequent (78.7%), typically involving hypertension (55.3%). Autoimmune disorders (25.5%), cancer (23.4%), and depression (21.3%) were also commonly reported. Although persisting memory problems were often noted, dementia was diagnosed in seven cases (14.9%). Life expectancy and comorbidities in TEA did not differ from available population norms. SIGNIFICANCE: Results suggest that life expectancy is not reduced in TEA. Although TEA does not appear to be a self‐limiting form of epilepsy, seizures are typically well controlled via medication. Because adjustments to medication may be required, even after long periods of stability, ongoing medical monitoring is recommended. Comorbid vascular disorders are frequent but appear similar to general population estimates. Monitoring mood may be important, given that people with chronic conditions are often vulnerable to depression. Because of persisting memory difficulties, the development of effective memory interventions for people with TEA is warranted.
format Online
Article
Text
id pubmed-9310913
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93109132022-07-29 Clinical outcomes in transient epileptic amnesia: A 10‐year follow‐up cohort study of 47 cases Savage, Sharon A. Baker, John Milton, Fraser Butler, Christopher Zeman, Adam Epilepsia Research Article OBJECTIVE: Transient epileptic amnesia (TEA) is a form of adult‐onset epilepsy where presenting features are well described, but little is known regarding prognosis. This study aimed to elucidate the long‐term prognosis of TEA regarding seizure control, memory, medical comorbidities, and life expectancy. METHODS: Up‐to‐date clinical information was collected for 47 people diagnosed with TEA who had joined the The Impairment of Memory in Epilepsy (TIME) study 10 years earlier. At entry to the study, information about comorbid conditions was systematically collected. Details regarding subsequent diagnoses, seizure activity, changes to treatment, or reports of cognitive impairment were obtained through the family doctor. The variables of interest were compared with UK population data. RESULTS: Mortality in the cohort was 21 of 47 (45%), with an average age at death of 82.5 years. Seizures remained well controlled for the majority but medications required adjustments in dose and type for some (28%). A small number (three cases) remained seizure‐free without medication. History of cardiovascular disorders was frequent (78.7%), typically involving hypertension (55.3%). Autoimmune disorders (25.5%), cancer (23.4%), and depression (21.3%) were also commonly reported. Although persisting memory problems were often noted, dementia was diagnosed in seven cases (14.9%). Life expectancy and comorbidities in TEA did not differ from available population norms. SIGNIFICANCE: Results suggest that life expectancy is not reduced in TEA. Although TEA does not appear to be a self‐limiting form of epilepsy, seizures are typically well controlled via medication. Because adjustments to medication may be required, even after long periods of stability, ongoing medical monitoring is recommended. Comorbid vascular disorders are frequent but appear similar to general population estimates. Monitoring mood may be important, given that people with chronic conditions are often vulnerable to depression. Because of persisting memory difficulties, the development of effective memory interventions for people with TEA is warranted. John Wiley and Sons Inc. 2022-03-18 2022-05 /pmc/articles/PMC9310913/ /pubmed/35253220 http://dx.doi.org/10.1111/epi.17214 Text en © 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Savage, Sharon A.
Baker, John
Milton, Fraser
Butler, Christopher
Zeman, Adam
Clinical outcomes in transient epileptic amnesia: A 10‐year follow‐up cohort study of 47 cases
title Clinical outcomes in transient epileptic amnesia: A 10‐year follow‐up cohort study of 47 cases
title_full Clinical outcomes in transient epileptic amnesia: A 10‐year follow‐up cohort study of 47 cases
title_fullStr Clinical outcomes in transient epileptic amnesia: A 10‐year follow‐up cohort study of 47 cases
title_full_unstemmed Clinical outcomes in transient epileptic amnesia: A 10‐year follow‐up cohort study of 47 cases
title_short Clinical outcomes in transient epileptic amnesia: A 10‐year follow‐up cohort study of 47 cases
title_sort clinical outcomes in transient epileptic amnesia: a 10‐year follow‐up cohort study of 47 cases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310913/
https://www.ncbi.nlm.nih.gov/pubmed/35253220
http://dx.doi.org/10.1111/epi.17214
work_keys_str_mv AT savagesharona clinicaloutcomesintransientepilepticamnesiaa10yearfollowupcohortstudyof47cases
AT bakerjohn clinicaloutcomesintransientepilepticamnesiaa10yearfollowupcohortstudyof47cases
AT miltonfraser clinicaloutcomesintransientepilepticamnesiaa10yearfollowupcohortstudyof47cases
AT butlerchristopher clinicaloutcomesintransientepilepticamnesiaa10yearfollowupcohortstudyof47cases
AT zemanadam clinicaloutcomesintransientepilepticamnesiaa10yearfollowupcohortstudyof47cases